You are given a text that consists of multiple sentences. Your task is to perform abstractive summarization on this text. Use your understanding of the content to express the main ideas and crucial details in a shorter, coherent, and natural sounding text.

CULVER CITY, Calif.--(BUSINESS WIRE)--NantHealth, Inc. (NASDAQ-GS: NH), a provider of enterprise solutions that help transform complex data into actionable insights, today reported financial results for its fourth quarter and full year ended December 31, 2020. While managing our business through the challenges associated with COVID-19 for most of the past year, we advanced our goal of expanding and diversifying NantHealth's software portfolio and services offerings with the acquisition of OpenNMS, continued to invest in our data solutions and AI capabilities, and delivered expanded capabilities on our NaviNet and Eviti SaaS products, said Ron Louks, Chief Operating Officer, NantHealth. In addition, as part of our NantHealth Cares initiative, we supported healthcare providers and medical staff by offering, at no cost for the entire month of May, our NaviNet AllPayer platform to providers. I am pleased to report that even with a month of free access, AllPayer revenues grew in 2020 and added more than 1,500 providers to its network." Software and Services Q4 Highlights: Network Monitoring and Management (OpenNMS) Precision Medicine and Artificial Intelligence - Highlights: Business and Financial Highlights For the 2020 fourth quarter: For the 2020 full year: At December 31, 2020, cash and cash equivalents totaled $22.8 million. Conference Call Information and Forward-Looking Statements Later today, the company will host a conference call at 1:30 p.m. PT (4:30 p.m. ET) to review its results of operations for the fourth quarter and full year ended December 31, 2020. The conference call will be available to interested parties by dialing 844-309-3709 from the U.S. or Canada, or 281-962-4864 from international locations, passcode 9786375. The call will be broadcast via the Internet at www.nanthealth.com. Listeners are encouraged to visit the website at least 10 minutes prior to the start of the scheduled presentation to register, download and install any necessary audio software. A playback of the call will be archived and accessible on the same website for at least three months. Discussion during the conference call may include forward-looking statements regarding topics such as the companys financial status and performance, regulatory and operational developments, and other comments the company may make about its future plans or prospects in response to questions from participants on the conference call. Use of Non-GAAP Financial Measures This news release contains references to Non-GAAP financial measures, including adjusted net loss and adjusted net loss per share, which are financial measures that are not prepared in conformity with United States generally accepted accounting principles (U.S. GAAP). The Companys management believes that the presentation of Non-GAAP financial measures provides useful supplementary information regarding operational performance, because it enhances an investors overall understanding of the financial results for the Companys core business. Additionally, it provides a basis for the comparison of the financial results for the Companys core business between current, past and future periods. Other companies may define these measures in different ways. Non-GAAP financial measures should be considered only as a supplement to, and not as a substitute for or as a superior measure to, financial measures prepared in accordance with U.S. GAAP. Non-GAAP per share numbers are calculated based on one class of common stock and do not incorporate the effects, if any, of using the two-class method. About NantHealth, Inc. NantHealth, a member of the NantWorks ecosystem of companies, provides enterprise solutions that help businesses transform complex data into actionable insights. By offering efficient ways to move, interpret, and visualize complex and highly sensitive information, NantHealth enables customers in healthcare, life sciences, logistics, telecommunications and other industries to automate, understand and act on data while keeping it secure and scalable. NantHealths product portfolio comprises the latest technology in payer/provider collaboration platforms for real-time coverage decision support (Eviti and NaviNet), molecular analysis (GPS Cancer), and data solutions that provide multi-data analysis, reporting and professional services offerings (Quadris). OpenNMS, a NantHealth subsidiary, helps businesses monitor and manage network health and performance. For more information, visit nanthealth.com, follow us on Twitter, Facebook and LinkedIn, and subscribe to our blog. This news release contains certain statements of a forward-looking nature relating to future events or future business performance. Forward-looking statements can be identified by the words expects, anticipates, believes, intends, estimates, plans, will, outlook and similar expressions. Forward-looking statements are based on managements current plans, estimates, assumptions and projections, and speak only as of the date they are made. Risks and uncertainties include, but are not limited to: our ability to successfully integrate our systems and solutions to address a wide range of healthcare issues; our ability to successfully amass the requisite data to achieve maximum network effects; appropriately allocating financial and human resources across a broad array of product and service offerings; raising additional capital as necessary to fund our operations; achieving significant commercial market acceptance for our solutions; establishing relationships with key thought leaders or key decision makers in order to attract, retain and renew partners and clients and obtain reimbursement for our sequencing and molecular analysis solutions; our ability to grow the market for our solutions; successfully enhancing our solutions to achieve market acceptance and keep pace with technological developments; customer concentration; competition; security breaches; data loss or corruption due to failures or errors in our systems and service disruptions at our data centers; bandwidth limitations; our ability to use, disclose, de-identify or license data and to integrate third-party technologies; our use of open source software; our ability to continue our relationship with NantOmics; our ability to obtain regulatory approvals; dependence upon senior management; the need to comply with and meet applicable laws and regulations; unexpected adverse events; clinical adoption and market acceptance of our molecular sequencing and analysis solutions; and anticipated cost savings. We undertake no obligation to update any forward-looking statement in light of new information or future events, except as otherwise required by law. Forward-looking statements involve inherent risks and uncertainties, most of which are difficult to predict and are generally beyond our control. Actual results or outcomes may differ materially from those implied by the forward-looking statements as a result of the impact of a number of factors, many of which are discussed in more detail in our reports filed with the Securities and Exchange Commission.. NantHealth, Inc. Consolidated Balance Sheets (Dollars in thousands, except per share amounts) (Unaudited) December 31, 2020 2019 Assets Current assets Cash and cash equivalents $ 22,787 $ 5,243 Accounts receivable, net 3,273 6,179 Related party receivables, net 1,031 823 Prepaid expenses and other current assets 3,504 19,341 Current assets of discontinued operations 6,327 Total current assets 30,595 37,913 Property, plant, and equipment, net 13,102 14,985 Goodwill 98,333 97,307 Intangible assets, net 47,969 51,848 Investment in related party 31,702 Related party receivable, net of current 823 1,108 Operating lease right-of-use assets 7,539 8,470 Other assets 1,927 1,818 Noncurrent assets of discontinued operations 21,336 Total assets $ 200,288 $ 266,487 Liabilities and Stockholders' Equity Current liabilities Accounts payable $ 5,122 $ 3,377 Accrued and other current liabilities 13,975 31,988 Deferred revenue 1,166 7,098 Related party payables, net 4,238 4,120 Notes payable 268 238 Related party convertible note, net 9,411 Convertible notes, net 90,578 Current liabilities of discontinued operations 10,680 Total current liabilities 124,758 57,501 Deferred revenue, net of current 393 1,129 Related party liabilities 31,091 24,227 Related party promissory note 112,666 112,666 Related party convertible note, net 8,864 Convertible notes, net 84,648 Deferred income taxes, net 1,853 1,669 Operating lease liabilities 8,170 9,728 Other liabilities 32,757 21,542 Noncurrent liabilities of discontinued operations 1,649 Total liabilities 311,688 323,623 Stockholders' deficit Common stock, $0.0001 par value per share, 750,000,000 shares authorized; 111,284,733 and 110,619,678 shares issued and outstanding at December 31, 2020 and 2019, respectively 11 11 Additional paid-in capital 891,583 889,955 Accumulated deficit (1,003,210) (946,884) Accumulated other comprehensive loss (168) (218) Total NantHealth stockholders' deficit (111,784) (57,136) Noncontrolling interests 384 Total stockholders' deficit (111,400) (57,136) Total liabilities and stockholders' deficit $ 200,288 $ 266,487 NantHealth, Inc. Consolidated Statements of Operations (Dollars in thousands, except per share amounts) (Unaudited) Three Months Ended December 31, Year Ended December 31, 2020 2019 2020 2019 Revenue Software-as-a-service related $ 18,201 $ 18,410 $ 72,198 $ 72,831 Maintenance 378 677 Professional services 24 86 Total software-related revenue 18,603 18,410 72,961 72,831 Sequencing and molecular analysis 39 152 211 1,733 Home health care services 2,863 Total net revenue 18,642 18,562 73,172 77,427 Cost of Revenue Software-as-a-service related 5,504 6,096 23,056 23,100 Maintenance 230 69 361 357 Professional services 1 16 Amortization of developed technologies 1,247 1,143 4,755 4,662 Total software-related cost of revenue 6,982 7,308 28,188 28,119 Sequencing and molecular analysis 211 480 1,038 4,546 Home health care services 1,471 Total cost of revenue 7,193 7,788 29,226 34,136 Gross Profit 11,449 10,774 43,946 43,291 Operating Expenses Selling, general and administrative 11,670 12,752 48,534 55,595 Research and development 4,828 3,431 17,274 13,934 Amortization of acquisition-related assets 985 1,054 3,676 4,216 Impairment of intangible assets, including internal-use software 729 729 3,977 Total operating expenses 18,212 17,237 70,213 77,722 Loss from operations (6,763) (6,463) (26,267) (34,431) Interest expense, net (4,908) (4,601) (19,199) (18,044) Other expense, net (8,274) (585) (10,824) (5,607) Loss from related party equity method investment (1,916) (31,702) (8,317) Loss from continuing operations before income taxes (19,945) (13,565) (87,992) (66,399) Provision for (benefit from) income taxes 273 (359) 447 (1,018) Net loss from continuing operations (20,218) (13,206) (88,439) (65,381) Income from discontinued operations, net of tax attributable to NantHealth 38 1,457 31,993 2,619 Net loss (20,180) (11,749) (56,446) (62,762) Net loss attributable to noncontrolling interests (78) (120) Net loss attributable to NantHealth $ (20,102) $ (11,749) $ (56,326) $ (62,762) Basic and diluted net loss per share attributable to NantHealth: Continuing operations - common stock $ (0.18) $ (0.12) $ (0.80) $ (0.59) Discontinued operations - common stock $ $ 0.01 $ 0.29 $ 0.02 Total net loss per share - common stock $ (0.18) $ (0.11) $ (0.51) $ (0.57) Weighted average shares outstanding Basic and diluted - common stock 111,238,540 110,619,780 110,954,858 110,351,638 NantHealth, Inc. Non-GAAP Net Loss from Continuing Operations Attributable to NantHealth and Non-GAAP Net Loss Per Share from Continuing Operations Attributable to NantHealth (Dollars in thousands, except per share amounts) (Unaudited) Three Months Ended December 31, Year Ended December 31, 2020 2019 2020 2019 Net loss from continuing operations attributable to NantHealth $ (20,140) $ (13,206) $ (88,319) $ (65,381) Adjustments to GAAP net loss from continuing operations attributable to NantHealth: Loss from related party equity method investment 1,916 31,702 8,317 Stock-based compensation expense from continuing operations 961 1,566 2,722 2,842 Change in fair value of derivatives liability (3) 4 Change in fair value of Bookings Commitment 8,098 372 11,168 5,036 Noncash interest expense related to convertible notes 1,698 1,495 6,477 5,702 Intangible amortization from continuing operations 2,212 2,197 8,395 8,878 Impairment of intangible assets, including internal-use software 729 729 3,977 Loss on sale of business 582 Securities litigation costs 28 (103) 528 Tax provision (benefit) resulting from certain noncash tax items 244 (51) 228 (570) Total adjustments to GAAP net loss from continuing operations attributable to NantHealth 13,939 7,523 61,322 35,292 Net loss from continuing operations attributable to NantHealth - Non-GAAP $ (6,201) $ (5,683) $ (26,997) $ (30,089) Weighted average basic common shares outstanding 111,238,540 110,619,780 110,954,858 110,351,638 Net loss per common share from continuing operations attributable to NantHealth - Non-GAAP $ (0.06) $ (0.05) $ (0.24) $ (0.27) Reconciliation of Net Loss per Common Share from Continuing Operations Attributable to NantHealth to Net Loss per Common Share from Continuing Operations Attributable to NantHealth - Non-GAAP (Unaudited): Three Months Ended December 31, Year Ended December 31, 2020 2019 2020 2019 Net loss per common share from continuing operations attributable to NantHealth $ (0.18) $ (0.12) $ (0.80) $ (0.59) Adjustments to GAAP net loss per common share from continuing operations attributable to NantHealth: Loss from related party equity method investment 0.03 0.29 0.07 Stock-based compensation expense from continuing operations 0.01 0.01 0.02 0.03 Change in fair value of derivatives liability Change in fair value of Bookings Commitment 0.07 0.10 0.05 Noncash interest expense related to convertible notes 0.01 0.01 0.06 0.05 Intangible amortization from continuing operations 0.02 0.02 0.08 0.08 Impairment of intangible assets, including internal-use software 0.01 0.01 0.04 Loss on sale of business 0.01 Securities litigation costs Tax provision (benefit) resulting from certain noncash tax items (0.01) Total adjustments to GAAP net loss per common share from continuing operations attributable to NantHealth 0.12 0.07 0.56 0.32 Net loss per common share from continuing operations attributable to NantHealth - Non-GAAP $ (0.06) $ (0.05) $ (0.24) $ (0.27)

Answer: NantHealth Reports 2020 Fourth-Quarter, Full-Year Financial Results Q4 Financial Highlights 2020 vs 2019: Total revenue was $18.6 million Total software-related revenue was $18.6 million, up from $18.4 million Total gross margin increased to 61% from 58% Full-Year Financial Highlights 2020 vs 2019: Total revenue was $73.2 million vs $77.4 million Total software-related revenue was $73.0 million, up from $72.8 million Total gross margin increased to 60% from 56% Completed sale of Connected Care Business for $47.25 million in February 2020 Acquired The OpenNMS Group, an open source network monitoring company, in July 2020